452 related articles for article (PubMed ID: 33410241)
1. VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
Watanabe H; Ichihara E; Kayatani H; Makimoto G; Ninomiya K; Nishii K; Higo H; Ando C; Okawa S; Nakasuka T; Kano H; Hara N; Hirabae A; Kato Y; Ninomiya T; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Cancer Sci; 2021 May; 112(5):1853-1864. PubMed ID: 33410241
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update.
Moes-Sosnowska J; Szpechcinski A; Chorostowska-Wynimko J
Tumour Biol; 2024; 46(s1):S309-S325. PubMed ID: 37840519
[TBL] [Abstract][Full Text] [Related]
3. MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling.
Chen N; Tyler LC; Le AT; Welsh EA; Fang B; Elliott A; Davies KD; Danhorn T; Riely GJ; Ladanyi M; Haura EB; Doebele RC
Mol Cancer Ther; 2024 Jan; 23(1):92-105. PubMed ID: 37748191
[TBL] [Abstract][Full Text] [Related]
4. MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF.
Kondo N; Utsumi T; Shimizu Y; Takemoto A; Oh-Hara T; Uchibori K; Subat-Motoshi S; Ninomiya H; Takeuchi K; Nishio M; Miyazaki Y; Katayama R
JCI Insight; 2023 Dec; 8(24):. PubMed ID: 37917191
[TBL] [Abstract][Full Text] [Related]
5. Fifty-five months progression-free survival with crizotinib treatment in coexistence of ALK and ROS1 rearrangements in lung adenocarcinoma: an extremely rare case and review of the literature.
Korkmaz M; Eryilmaz MK
Anticancer Drugs; 2022 Jan; 33(1):e799-e801. PubMed ID: 34459458
[TBL] [Abstract][Full Text] [Related]
6. Crizotinib inhibition of
Bebb DG; Agulnik J; Albadine R; Banerji S; Bigras G; Butts C; Couture C; Cutz JC; Desmeules P; Ionescu DN; Leighl NB; Melosky B; Morzycki W; Rashid-Kolvear F; Lab C; Sekhon HS; Smith AC; Stockley TL; Torlakovic E; Xu Z; Tsao MS
Curr Oncol; 2019 Aug; 26(4):e551-e557. PubMed ID: 31548824
[TBL] [Abstract][Full Text] [Related]
7. Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement.
Krawczyk P; Grenda A; Terlecka P; Błach J; Wojas-Krawczyk K; Kucharczyk T; Chmielewska I; Kieszko R; Jarosz B; Gil M; Reszka K; Milanowski J
Sci Rep; 2021 Oct; 11(1):20939. PubMed ID: 34686712
[TBL] [Abstract][Full Text] [Related]
8. Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non-small Cell Lung Cancers.
Bagnyukova T; Egleston BL; Pavlov VA; Serebriiskii IG; Golemis EA; Borghaei H
Cancer Res Commun; 2024 May; 4(5):1227-1239. PubMed ID: 38639476
[TBL] [Abstract][Full Text] [Related]
9. Personalized therapy for lung cancer: striking a moving target.
Pakkala S; Ramalingam SS
JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089719
[TBL] [Abstract][Full Text] [Related]
10. Personalized targeted therapy for lung cancer.
Wu K; House L; Liu W; Cho WCS
Int J Mol Sci; 2012; 13(9):11471-11496. PubMed ID: 23109866
[TBL] [Abstract][Full Text] [Related]
11. The role of anti-angiogenesis in non-small-cell lung cancer: an update.
Villaruz LC; Socinski MA
Curr Oncol Rep; 2015 Jun; 17(6):26. PubMed ID: 25947099
[TBL] [Abstract][Full Text] [Related]
12. SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors.
Xia ZJ; Ji YC; Sun DQ; Peng X; Gao YL; Fang YF; Zhao XD; Wang WB; Ding J; Geng MY; Ai J
Acta Pharmacol Sin; 2021 Jun; 42(6):998-1004. PubMed ID: 32918045
[TBL] [Abstract][Full Text] [Related]
13. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.
Haderk F; Chou YT; Cech L; Fernández-Méndez C; Yu J; Olivas V; Meraz IM; Barbosa Rabago D; Kerr DL; Gomez C; Allegakoen DV; Guan J; Shah KN; Herrington KA; Gbenedio OM; Nanjo S; Majidi M; Tamaki W; Pourmoghadam YK; Rotow JK; McCoach CE; Riess JW; Gutkind JS; Tang TT; Post L; Huang B; Santisteban P; Goodarzi H; Bandyopadhyay S; Kuo CJ; Roose JP; Wu W; Blakely CM; Roth JA; Bivona TG
Nat Commun; 2024 May; 15(1):3741. PubMed ID: 38702301
[TBL] [Abstract][Full Text] [Related]
14. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.
Robinson KW; Sandler AB
Oncologist; 2013; 18(2):115-22. PubMed ID: 23345546
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
Moro-Sibilot D; Cozic N; Pérol M; Mazières J; Otto J; Souquet PJ; Bahleda R; Wislez M; Zalcman G; Guibert SD; Barlési F; Mennecier B; Monnet I; Sabatier R; Bota S; Dubos C; Verriele V; Haddad V; Ferretti G; Cortot A; De Fraipont F; Jimenez M; Hoog-Labouret N; Vassal G
Ann Oncol; 2019 Dec; 30(12):1985-1991. PubMed ID: 31584608
[TBL] [Abstract][Full Text] [Related]
16. Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers.
Tan AC; Itchins M; Khasraw M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093103
[TBL] [Abstract][Full Text] [Related]
17. Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.
Chong CR; Bahcall M; Capelletti M; Kosaka T; Ercan D; Sim T; Sholl LM; Nishino M; Johnson BE; Gray NS; Jänne PA
Clin Cancer Res; 2017 Jan; 23(1):204-213. PubMed ID: 27370605
[TBL] [Abstract][Full Text] [Related]
18. CD74-ROS1 L2026M mutant enhances autophagy through the MEK/ERK pathway to promote invasion, metastasis and crizotinib resistance in non-small cell lung cancer cells.
Xu X; Li Y; Xu R; Meng Y; Li Z; Zuo D; Wu Y
FEBS J; 2024 Mar; 291(6):1199-1219. PubMed ID: 38148635
[TBL] [Abstract][Full Text] [Related]
19. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.
Sun Q; Zhou J; Zhang Z; Guo M; Liang J; Zhou F; Long J; Zhang W; Yin F; Cai H; Yang H; Zhang W; Gu Y; Ni L; Sai Y; Cui Y; Zhang M; Hong M; Sun J; Yang Z; Qing W; Su W; Ren Y
Cancer Biol Ther; 2014; 15(12):1635-45. PubMed ID: 25482937
[TBL] [Abstract][Full Text] [Related]
20. YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models.
Xu Y; Lin H; Meng N; Lu W; Li G; Han Y; Dai X; Xia Y; Song X; Yang S; Wei Y; Yu L; Zhao Y
Br J Pharmacol; 2013 Aug; 169(8):1766-80. PubMed ID: 23594209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
